QRx Pharma Ltd: Janette Dixon. Addressing the need for a better safer opioid product with MoxDuo-IR

Polytherics close series C funding: John Burt discusses the funding environment leading up to their latest round

Prosensa: Luc Dochez. Using their RNA modulating platform to help patients with Duchenne's, Myotonic Dystrophy and Huntington’s

Molmed: Holger Neecke. How their TK cell-based therapy could offer a potential solution to patients unable to find a fully matched

Biosceptre: Cliff Holloway discusses developing their antibodies to nf-P2X7 for therapeutic and diagnostic applications in cancer